Delivery Order SPE2DB20D3303-SPE2DB25FA2KT
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) on August 15, 2025, with a ceiling value of $4,198.84. This firm fixed-price delivery order is set to be completed by August 18, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 50 mg capsules (100 count) with a contract ceiling value of $4,076.22. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,395.19 for Vyvanse 60 mg capsules (100-count units) on August 5, 2025, with completion targeted for August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) valued at $3,100.35, with a firm fixed price structure and no set-aside designation. The award was issued on September 15, 2025, with an ultimate completion date of September 16, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2KTDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,121.45 for Vyvanse 60 mg capsules (100-count units) on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a discrete transaction under AmerisourceBergen's broader federal contract portfolio supporting military and veteran healthcare procurement. This award is a child contract issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive prime vendor agreement enables the contractor to supply a full spectrum of pharmaceutical products and medical supplies, including both brand-name and generic medications, to support Defense Health Agency operations and other federal healthcare systems worldwide. The current delivery order for Vyvanse—a prescription stimulant medication commonly prescribed for attention deficit hyperactivity disorder—reflects the contractor's ongoing role as a critical supplier within the DLA's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/12/25 |